TN-401 demonstrated significant efficacy in preventing ARVC development and in extending median lifespan by ≥ 58 weeks, far beyond the 4.7 weeks observed in the vehicle-treated Pkp2-cKO animals (Fig. 4e). Here, PKP2 is linked to arrhythmogenic right ventricular cardiomyopathy.